ImmunityBio stock rallied after Chairman Patrick Soon-Shiong credited talks with President Trump and the Saudi Crown Prince for accelerating Anktiva approvals. Recent wins include EU authorisation for bladder cancer and new lung cancer approvals. While IBRX hits 2024 highs, traders are closely watching record short interest of 13.7% amid increased retail activity.